Philadelphia personal injury lawyers have learned that the Food and Drug Administration (FDA) recently announced that Xolair, an injectqable asthma treatment, is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems.
The FDA added information about the increased risks to the drug’s label after analyzing findings from a five-year safety study submitted by the drug’s manufacturer, Genentech, a unit of Roche Holding AG, and 25 clinical trials comparing Xolair to a placebo.
Xolair is an injectable drug that was originally approved in 2003 to treat moderate to severe asthma in adults and children ages 12 or over whose condition was not controlled by inhaled steroids. The drug is also approved to treat a chronic form of hives in adults and adolescents.
The FDA said that the recent data is suggestive of a serious safety signal. The problems involve the blood vessels supplying the heart and brain, the FDA said, and include a greater risk of pulmonary hypertension, or high blood pressure in the arteries of the lungs.
The Philadelphia personal injury lawyers at Messa & Associates are experienced at handling cases involving pharmaceutical and drug product injuries. Our extremely skilled team of personal injury lawyers and medical experts is dedicated to ensuring you receive proper compensation for your personal injuries. If you or a loved one has suffered a serious reaction to Xolair, a defective pharmaceutical drug product, or any other type of personal injury, you may wish to confer with a lawyer who can help you obtain compensation for medical expenses, pain and suffering, and more. Contact the personal injury lawyers of Messa & Associates for a free consultation. Call toll free at 1-877-MessaLaw, or submit a free online inquiry to learn more about your legal rights and options to file a Xolair lawsuit.
Joseph L. Messa, Jr. is the founding partner of Messa & Associates, P.C. He is an AV-rated attorney (highest rating available), listed in the Bar Register of Preeminent Lawyers. Read More